AVA-004 / Avacta, LG Chem - LARVOL DELTA

LG Chem Renews License Triggering Payment to Avacta (Businesswire) - "Avacta Group plc...announce that LG Chem Life Sciences...has exercised its renewal option as part of the ongoing collaboration with Avacta, triggering a license renewal fee payment to Avacta of $2 million. Under the terms of the agreement, LG Chem has the exclusive rights to develop and commercialise, on a global basis, Avacta’s Affimer® PD-L1 inhibitor with Affimer XT™ serum half-life extension for a range of indications. LG Chem has exercised its license renewal option and will progress the PD-L1/XT candidate by commencing pre-clinical studies which are intended to form the basis of an Investigational New Drug (IND) submission."

Licensing / partnership • Oncology

[VIRTUAL] Pharmacokinetics and biodistribution of formatted Affimer® biotherapeutics targeting PD-L1 (AACR 2021) - "A more quantitative biodistribution study was conducted in the same model using SPECT imaging DOTAGA bioconjugated AVA004 Fc molecules radiolabeled with 111Indium. The imaging biodistribution allowed us to select the most favorable molecule based on its tumor/plasma and tumor/liver ratios."

PK/PD data • Oncology

Generation and formatting of an Affimer biotherapeutic for the inhibition of the PD-L1/PD-1 pathway: Proof of concept in mouse (AACR 2018) - "We have demonstrated that the Affimer scaffold has all the necessary attributes to be developed as a therapeutic platform. The Affimer scaffold was well tolerated in vivo, demonstrated a potency and PK profile that ensured sufficient exposure in the animal to modulate the immune system to slow tumor progression in a relevant mouse model."

Preclinical • Non Small Cell Lung Cancer

Avacta Group plc hits clinical candidate selection milestone for Affimer PD-L1 inhibitor (Businesswire) - "Avacta Group plc...announces that it has selected the clinical development candidate for first-time-in-human clinical trials of the Affimer platform. This important milestone means that the Group remains on track to submit an IND/CTA application for an Affimer PD-L1 inhibitor by the end of 2020...Avacta has selected a specific Affimer molecule (AVA004) as its clinical candidate because of its excellent in vitro and in vivo pharmacological properties."

IND • Pipeline update